• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Nature's Sunshine Reports Second Quarter 2025 Results

    7/31/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email

    LEHI, Utah, July 31, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the second quarter ended June 30, 2025.

    Second Quarter 2025 Financial Summary vs. Same Year-Ago Quarter

    • Net sales were up 4% to $114.8 million compared to $110.6 million (up 2% in constant currency).
    • GAAP net income attributable to common shareholders was $5.3 million, or $0.28 per diluted common share, compared to $1.3 million, or $0.07 per diluted common share.
    • Adjusted EBITDA was up 8% to $11.3 million compared to $10.4 million.



    Management Commentary

    "We delivered another strong quarter, with net sales of $115 million and adjusted EBITDA of $11 million, up 4% and 8%, respectively, year-over-year," said Terrence Moorehead, CEO of Nature's Sunshine. "We're particularly encouraged by the strength we continued to see in Japan and Central Europe, as well as sustained momentum in our digital business and auto ship program. These results underscore the effectiveness of our global strategy and the progress we've made strengthening fundamentals in North America. While the macroeconomic environment remains uncertain, we're confident in the underlying health of the business and our ability to drive sustainable growth going forward."

    Second Quarter 2025 Financial Results

      Net Sales by Operating Segment (Amounts in Thousands)
    Three Months Ended June 30,  2025  2024 Percent

    Change
     Impact of

    Currency

    Exchange
     Percent

    Change

    Excluding

    Impact of

    Currency
    Asia $52,664 $49,984 5.4% $1,523  2.3%
    Europe  21,741  21,602 0.6   483  (1.6)
    North America  34,977  33,563 4.2   (25) 4.3 
    Latin America and Other  5,368  5,402 (0.6)  (184) 2.8 
      $114,750 $110,551 3.8% $1,797  2.2%
                     

    Net sales in the second quarter increased 4% to $114.8 million compared to $110.6 million in the same year-ago quarter. Excluding the impact from foreign exchange rates, net sales in the second quarter of 2025 increased 2% compared to the year-ago quarter.

    Gross profit margin in the second quarter increased to 71.7% compared to 71.4% in the year-ago quarter. The increase was driven by cost savings initiatives, partially offset by unfavorable foreign exchange and market mix.

    Volume incentives as a percentage of net sales were 29.9% compared to 31.4% in the year-ago quarter. The decrease was primarily due to timing of promotional incentives and changes in product pricing and market mix.

    Selling, general and administrative expenses ("SG&A") in the second quarter were $43.7 million compared to $38.6 million in the year‐ago quarter. The increase was primarily related to the timing of compensation costs, incremental investment in digital marketing and other non-recurring expenses. As a percentage of net sales, SG&A expenses were 38.1% for the second quarter of 2025 compared to 34.9% in the year-ago quarter.

    Operating income in the second quarter decreased to $4.3 million, or 3.7% of net sales, compared to $5.6 million, or 5.1% of net sales, in the year-ago quarter.

    Other income (loss), net, in the second quarter of 2025 was $3.3 million compared to $(1.2) million in the second quarter of 2024. Other income (loss), net, primarily consisted of foreign exchange gains in Asia and Europe, partially offset by foreign exchange losses in Latin America and North America that resulted from net changes in foreign currencies. The provision for income taxes was $2.0 million in the second quarter of 2025 compared to $2.9 million for the year-ago quarter.

    GAAP net income attributable to common shareholders increased to $5.3 million, or $0.28 per diluted common share, compared to $1.3 million, or $0.07 per diluted common share, in the second quarter of 2024. Net income attributable to NSP China increased to $0.9 million, or $0.05 per diluted common share, for the second quarter of 2025, compared to $0.7 million, or $0.04 per diluted common share, for the second quarter of 2024.

    Adjusted EBITDA in the second quarter increased 8% to $11.3 million compared to $10.4 million in the prior year quarter. The increase was driven primarily by the increase in net sales. Adjusted EBITDA, which is a non-GAAP financial measure, is defined here as net income from continuing operations before taxes, depreciation, amortization, and other income (loss) adjusted to exclude share-based compensation expense and certain noted adjustments. A reconciliation of net income to adjusted EBITDA is provided in the attached financial tables.

    Balance Sheet and Cash Flow

    Net cash provided by operating activities was $6.9 million for the six months ended June 30, 2025, compared to $3.5 million in the prior year period. Capital expenditures during the six months ended June 30, 2025, totaled $2.5 million compared to $7.0 million in the comparable period of 2024. During the six months ended June 30, 2025, the Company repurchased 1,011,000 shares at a total cost of $12.4 million or $12.22 per share. As of June 30, 2025, the Company had cash and cash equivalents of $81.3 million and zero debt.

    Outlook

    Nature's Sunshine now expects full year 2025 net sales to range between $460 - $475 million ($445 - $470 million prior) and adjusted EBITDA to range between $41 - $45 million ($38 - $44 million prior).

    Conference Call

    The Company will hold a conference call today at 5:00 p.m. Eastern time to discuss its second quarter of 2025 results.

    Date: Thursday, July 31, 2025

    Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)

    Toll-free dial-in number: 1-800-717-1738

    International dial-in number: 1-646-307-1865

    Conference ID: 14947

    Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.

    The conference call will be broadcast live and available for replay here and via the Events section of the Nature's Sunshine website here.

    A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through August 14, 2025.

    Toll-free replay number: 1-844-512-2921

    International replay number: 1-412-317-6671

    Replay ID: 1114947

    About Nature's Sunshine Products

    Nature's Sunshine Products (NASDAQ:NATR), a leading natural health and wellness company, markets and distributes nutritional and personal care products in more than 40 countries. Nature's Sunshine manufactures most of its products through its own state-of-the-art facilities to ensure its products continue to set the standard for the highest quality, safety, and efficacy on the market today. Additional information about the company can be obtained at its website, www.naturessunshine.com.

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

    This press release contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected improvements in gross profit and gross margin. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the following:

    • extensive government regulations to which the Company's products, business practices and manufacturing activities are subject, including, but not limited to, trade restrictions and export controls;
    • registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
    • legal challenges to the Company's direct selling program or to the classification of its independent consultants;
    • laws and regulations regarding direct selling may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets;
    • liabilities and obligations arising from improper activity by the Company's independent consultants;
    • product liability claims;
    • impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
    • the Company's ability to attract and retain independent consultants;
    • the loss of one or more key independent consultants who have a significant sales network;
    • the effect of fluctuating foreign exchange rates;
    • failure of the Company's independent consultants to comply with advertising laws;
    • changes to the Company's independent consultants' compensation plans;
    • geopolitical issues and conflicts, including changes to U.S. trade policy resulting in new or additional tariffs;
    • negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company's customers to purchase products;
    • risks associated with the manufacturing of the Company's products;
    • supply chain disruptions, manufacturing interruptions or delays, or the failure to accurately forecast customer demand;
    • failure to timely and effectively obtain shipments of products from our suppliers and contract manufacturers and deliver products to our independent consultants and customers;
    • world-wide slowdowns and delays related to supply chain, ingredient shortages and logistical challenges;
    • uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
    • changes in tax laws, treaties or regulations, or their interpretation;
    • failure to maintain an effective system of internal controls over financial reporting;
    • cybersecurity threats and exposure to data loss;
    • the storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations;
    • reliance on information technology infrastructure; and
    • the sufficiency of trademarks and other intellectual property rights.



    These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption "Risk Factors" in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q.

    All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this press release. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this press release.

    Non-GAAP Financial Measures

    We have included information which has not been prepared in accordance with generally accepted accounting principles (GAAP), such as information concerning non-GAAP net income, adjusted EBITDA and net sales excluding the impact of foreign currency exchange fluctuations.

    We utilize the non-GAAP measures of non-GAAP net income and adjusted EBITDA in the evaluation of our operations and believe that these measures are useful indicators of our ability to fund our business. These non-GAAP financial measures should not be considered as an alternative to, or more meaningful than, U.S. GAAP net income (loss) as an indicator of our operating performance.

    Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of Nature's Sunshine Products' performance in relation to other companies. We have included a reconciliation of net income, the most comparable GAAP measure, to adjusted EBITDA. We have also included a reconciliation of GAAP net income to non-GAAP net income and non-GAAP adjusted EPS, in the attached financial tables.

    Net sales in local currency removes, from net sales in U.S. dollars, the impact of changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries. This is accomplished by translating the current period's net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period.

    We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. Net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

    With respect to our adjusted EBITDA outlook for the full year 2025, a quantitative reconciliation to the corresponding GAAP information cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted, including but not limited to warrant liabilities and stock based compensation. For the same reasons, we are unable to assess the probable significance of the unavailable information, which could have a material impact on our future GAAP financial results.

    Investor Relations:

    Gateway Group, Inc.

    Cody Slach

    1-949-574-3860

    [email protected]

        
    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (Amounts in thousands, except per share information)

    (Unaudited)
        
     Three Months Ended

    June 30,
     Six Months Ended

    June 30,
      2025   2024   2025   2024 
    Net sales$114,750  $110,551  $227,998  $221,544 
    Cost of sales 32,451   31,664   64,102   63,679 
    Gross profit 82,299   78,887   163,896   157,865 
            
    Operating expenses:       
    Volume incentives 34,360   34,693   69,204   68,263 
    Selling, general and administrative 43,665   38,557   84,246   79,341 
    Operating income 4,274   5,637   10,446   10,261 
    Other income (loss):       
    Interest and other income, net 268   412   473   475 
    Interest expense (24)  (103)  (45)  (115)
    Foreign exchange gains (losses), net 3,026   (1,523)  3,779   (1,543)
      3,270   (1,214)  4,207   (1,183)
    Income before provision for income taxes 7,544   4,423   14,653   9,078 
    Provision for income taxes 2,025   2,935   4,250   5,100 
    Net income 5,519   1,488   10,403   3,978 
    Net income attributable to noncontrolling interests 186   139   323   308 
    Net income attributable to common shareholders$5,333  $1,349  $10,080  $3,670 
            
    Basic and diluted net income per common share:       
            
    Basic earnings per share attributable to common shareholders$0.29  $0.07  $0.55  $0.20 
            
    Diluted earnings per share attributable to common shareholders$0.28  $0.07  $0.54  $0.19 
            
    Weighted average basic common shares outstanding 18,406   18,647   18,446   18,737 
    Weighted average diluted common shares outstanding 18,966   19,119   18,832   19,184 
                    



    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands)

    (Unaudited)
        
     June 30,

    2025
     December 31,

    2024
    Assets   
    Current assets:   
    Cash and cash equivalents$81,345  $84,700 
    Accounts receivable, net of allowance for doubtful accounts of $93 and $97, respectively 13,029   9,477 
    Inventories 69,320   59,443 
    Prepaid expenses and other 8,144   6,959 
    Total current assets 171,838   160,579 
        
    Property, plant and equipment, net 35,930   39,585 
    Operating lease right-of-use assets 14,218   12,799 
    Restricted investment securities - trading 1,041   915 
    Deferred income tax assets 21,410   17,644 
    Other assets 10,438   9,333 
    Total assets$254,875  $240,855 
        
    Liabilities and Shareholders' Equity   
    Current liabilities:   
    Accounts payable$9,924  $8,912 
    Accrued volume incentives and service fees 22,583   20,563 
    Accrued liabilities 27,456   25,399 
    Deferred revenue 5,501   2,774 
    Income taxes payable 5,765   4,117 
    Current portion of operating lease liabilities 4,625   3,927 
    Total current liabilities 75,854   65,692 
        
    Liability related to unrecognized tax benefits 638   628 
    Long-term portion of operating lease liabilities 11,005   10,277 
    Deferred compensation payable 1,041   915 
    Deferred income tax liabilities 1,009   1,007 
    Other liabilities 1,646   1,345 
    Total liabilities 91,193   79,864 
        
    Commitments and contingencies   
        
    Shareholders' equity:   
    Common stock, no par value, 50,000 shares authorized, 17,635 and 18,483 shares issued and outstanding, respectively 104,662   114,577 
    Retained earnings 67,487   57,407 
    Noncontrolling interest 6,001   5,678 
    Accumulated other comprehensive loss (14,468)  (16,671)
    Total shareholders' equity 163,682   160,991 
    Total liabilities and shareholders' equity$254,875  $240,855 
            



    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Amounts in thousands)

    (Unaudited)
             
    Six Months Ended June 30,  2025   2024 
    CASH FLOWS FROM OPERATING ACTIVITIES:    
    Net income $10,403  $3,978 
    Adjustments to reconcile net income to net cash provided by operating activities:    
    Depreciation and amortization  6,999   6,659 
    Non-cash lease expense  2,675   3,298 
    Share-based compensation expense  2,938   2,630 
    Deferred income taxes  (3,179)  (14)
    Purchase of trading investment securities  (78)  (110)
    Proceeds from sale of trading investment securities  11   40 
    Realized and unrealized gains on investments  (59)  (72)
    Foreign exchange losses (gains)  (3,779)  1,543 
    Changes in assets and liabilities:    
    Accounts receivable  (2,963)  (2,960)
    Inventories  (7,901)  3,112 
    Prepaid expenses and other current assets  (1,349)  (2,162)
    Other assets  (355)  (598)
    Accounts payable  790   409 
    Accrued volume incentives and service fees  1,193   (144)
    Accrued liabilities  325   (7,993)
    Deferred revenue  2,583   477 
    Lease liabilities  (2,684)  (3,215)
    Income taxes payable  824   (2,251)
    Liability related to unrecognized tax benefits  429   726 
    Deferred compensation payable  126   142 
    Net cash provided by operating activities  6,949   3,495 
    CASH FLOWS FROM INVESTING ACTIVITIES:    
    Purchases of property, plant and equipment  (2,460)  (7,040)
    Net cash used in investing activities  (2,460)  (7,040)
    CASH FLOWS FROM FINANCING ACTIVITIES:    
    Proceeds from revolving credit facility  1,823   34,216 
    Principal payments of revolving credit facility  (1,823)  (34,216)
    Payments related to tax withholding for net-share settled equity awards  (499)  (586)
    Repurchase of common stock  (12,354)  (7,725)
    Net cash used in financing activities  (12,853)  (8,311)
    Effect of exchange rates on cash and cash equivalents  5,009   (1,822)
    Net decrease in cash and cash equivalents  (3,355)  (13,678)
    Cash and cash equivalents at the beginning of the period  84,700   82,373 
    Cash and cash equivalents at the end of the period $81,345  $68,695 
    SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
    Cash paid for income taxes, net of refunds $6,211  $8,144 
    Cash paid for interest  45   115 
             



    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA

    (Amounts in thousands)

    (Unaudited)
        
     Three Months Ended

    June 30,
     Six Months Ended

    June 30,
      2025   2024  2025   2024
    Net income$5,519  $1,488 $10,403  $3,978
    Adjustments:       
    Depreciation and amortization 3,500   3,499  6,999   6,659
    Share-based compensation expense 1,638   1,261  2,938   2,630
    Other (income) loss, net* (3,270)  1,214  (4,207)  1,183
    Provision for income taxes 2,025   2,935  4,250   5,100
    Other adjustments (1) 1,853   —  1,853   —
    Adjusted EBITDA$11,265  $10,397 $22,236  $19,550
            
            
    (1) Other adjustments       
    Other non-recurring expenses$1,853  $— $1,853  $—
    Total adjustments$1,853  $— $1,853  $—
                  

    * Other (income) loss, net is primarily comprised of foreign exchange (gains) losses, interest income, and interest expense.

        
    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    RECONCILIATION OF GAAP NET INCOME TO

    NON-GAAP NET INCOME and NON-GAAP ADJUSTED EPS

    (Amounts in thousands)

    (Unaudited)
        
     Three Months Ended

    June 30,
     Six Months Ended

    June 30,
      2025   2024  2025   2024
    Net income$5,519  $1,488 $10,403  $3,978
    Adjustments:       
    Other non-recurring expenses 1,853   —  1,853   —
    Tax impact of adjustments (463)  —  (463)  —
    Total adjustments 1,390   —  1,390   —
    Non-GAAP net income$6,909  $1,488 $11,793  $3,978
            
    Reported income attributable to common shareholders$5,333  $1,349 $10,080  $3,670
    Total adjustments 1,390   —  1,390   —
    Non-GAAP net income attributable to common shareholders$6,723  $1,349 $11,470  $3,670
            
    Basic income per share, as reported$0.29  $0.07 $0.55  $0.20
    Total adjustments, net of tax 0.08   —  0.08   —
    Basic income per share, as adjusted$0.37  $0.07 $0.63  $0.20
            
    Diluted income per share, as reported$0.28  $0.07 $0.54  $0.19
    Total adjustments, net of tax 0.07   —  0.07   —
    Diluted income per share, as adjusted$0.35  $0.07 $0.61  $0.19
                  


    Primary Logo

    Get the next $NATR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    SEC Filings

    View All

    SEC Form 10-Q filed by Nature's Sunshine Products Inc.

    10-Q - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    7/31/25 5:11:25 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    7/31/25 4:09:48 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    7/7/25 4:17:43 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Accounting Officer Lanoy Jonathan David sold $82,550 worth of shares (5,000 units at $16.51), decreasing direct ownership by 9% to 50,051 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    8/15/25 12:45:08 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Brower Nathan G sold $165,334 worth of shares (9,996 units at $16.54), decreasing direct ownership by 17% to 48,277 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    8/15/25 12:12:35 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Prescott Group Capital Management, L.L.C. claimed ownership of 1,783,097 shares (SEC Form 3)

    3 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    8/11/25 12:51:44 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson resumed coverage on Nature's Sunshine with a new price target

    DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

    5/7/25 8:37:48 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

    Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

    9/13/24 7:38:59 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

    DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

    3/9/22 9:23:08 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nature's Sunshine Reports Second Quarter 2025 Results

    LEHI, Utah, July 31, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4% to $114.8 million compared to $110.6 million (up 2% in constant currency).GAAP net income attributable to common shareholders was $5.3 million, or $0.28 per diluted common share, compared to $1.3 million, or $0.07 per diluted common share.Adjusted EBITDA was up 8% to $11.3 million compared to $10.4 million. Management Commentary "We deli

    7/31/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gateway Group Announces Preliminary Sponsors and Presenting Companies for 2025 Gateway Conference

    NEWPORT BEACH, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Gateway Group ("Gateway"), a leading financial communications and digital media advisory firm, today announced the initial sponsors and presenting companies confirmed for its annual Gateway Conference taking place at the Four Seasons Hotel in San Francisco on September 3rd and 4th. The conference is expected to host more than 300 institutional investors and analysts for two days of company presentations and curated one-on-one meetings with executives from high-growth public and private companies across the tech, AI, cleantech, consumer, financial services, and industrials sectors. "We appreciate the strong support from our sponsors

    7/30/25 8:30:00 AM ET
    $ACNT
    $AIRG
    $AKA
    Steel/Iron Ore
    Industrials
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Nature's Sunshine Sets Second Quarter 2025 Conference Call for Thursday, July 31, 2025, at 5:00 p.m. ET

    LEHI, Utah, July 17, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, July 31, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the second quarter ended June 30, 2025. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Thursday, July 31, 2025Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)Toll-fr

    7/17/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Financials

    Live finance-specific insights

    View All

    Nature's Sunshine Reports Second Quarter 2025 Results

    LEHI, Utah, July 31, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4% to $114.8 million compared to $110.6 million (up 2% in constant currency).GAAP net income attributable to common shareholders was $5.3 million, or $0.28 per diluted common share, compared to $1.3 million, or $0.07 per diluted common share.Adjusted EBITDA was up 8% to $11.3 million compared to $10.4 million. Management Commentary "We deli

    7/31/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets Second Quarter 2025 Conference Call for Thursday, July 31, 2025, at 5:00 p.m. ET

    LEHI, Utah, July 17, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, July 31, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the second quarter ended June 30, 2025. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Thursday, July 31, 2025Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)Toll-fr

    7/17/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Reports Strong First Quarter 2025 Results

    LEHI, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million. Capital Allocation Na

    5/6/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    View All

    Nature's Sunshine Announces Leadership Transition Plan

    Board Initiates CEO Search Process Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed Company Reaffirms Full Year 2025 Outlook LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors. The Nature's Sunshine Board ha

    6/2/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Heidi Wissmiller as Chairman of the Board

    LEHI, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the appointment of Heidi Wissmiller as Chairman of the Board of Directors, effective April 30, 2025. She succeeds Richard D. Moss, who has retired after serving as a Director since 2018 and Chairman since 2022. Ms. Wissmiller has served on the Board of Nature's Sunshine since 2020. Over the course of her tenure, she has chaired the Governance and Risk Management Committees. As Chief Growth Officer at Rodan + Fields ("R+F"), the leading skincare brand in North America, Ms. Wissmiller led

    5/5/25 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Katie A. May to Board of Directors

    LEHI, Utah, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Ms. Katie A. May to its board of directors effective January 30, 2025. Nature's Sunshine's board will now consist of ten directors with nine serving as independent directors. "Katie brings significant experience scaling and leading high-growth B2C, ecommerce and logistics companies," said Richard D. Moss, Chairman of the Board of Nature's Sunshine. "Her deep understanding of the full ecommerce lifecycle will strengthen and enhance our digital capabilities and drive s

    2/5/25 4:05:00 PM ET
    $NATR
    $PBI
    $STMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Office Equipment/Supplies/Services
    Miscellaneous

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/12/24 10:37:49 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    1/31/24 11:56:05 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/13/23 2:42:04 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care